The third and final part of my conversation with Drs. Tom Hensing from North Shore Health System in Chicago and David Jackman from Dana Farber Cancer Institute in Boston covered a presentation of an Asian never-smoking woman with an advanced lung adenocarcinoma, the demographic picture most closely associated with potentially but not necessarily having an EGFR mutation or ALK rearrangement.

We cover the question of whether, in someone with a significant probability of one of these particular molecular markers, it's worth obtaining tissue and delaying treatment to tailor treatment on the basis of these results. We also discuss the range of options for maintenance therapy in someone who has many alternatives for continuing one or more agents from the first line setting or switching to a new treatment. Finally, we turn to the question of managing treatment for a patient who has a prolonged response to an EGFR inhibitor and then develops an acquired resistance to that therapy.

Here's the audio and video podcasts of the discussion, along with the transcript and figures.

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-3-audio-podcast

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-3-transcript

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-3-figures

This program was sponsored by OSI Pharmaceuticals, who had no input in its content. We appreciate their support in making this activity possible.